Filing identity and reporting period
The supplied filing is Skyline Medical Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not an Axe Compute Inc. filing. Skyline describes itself as a development-stage medical-device company selling the STREAMWAY surgical-fluid disposal system and related disposable kits. The filing reports a 1-for-75 reverse stock split effective October 24, 2014; amounts and share counts below reflect the filing’s presentation.
Financial performance and position
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | $151,274 | $70,220; up about 115% |
| Cost of goods sold | $95,968 | $31,083 |
| Gross profit / margin | $55,306 / about 37% | $39,137 |
| Net loss available to common shareholders | $225,795 | $1,616,993 |
| Loss per share, basic and diluted | $0.07 | $0.55 |
| Net cash used in operating activities | $5,231 | $1,752,443 |
| Cash at period-end | $3,453 | $130,738 |
At March 31, 2015, total assets were $724,917, total liabilities were $6,269,679, and stockholders’ deficit was $5,544,762. Current assets of $474,165 compared with current liabilities of $6,066,223, a working-capital deficit of approximately $5.59 million. Accounts payable were $2.46 million and accrued expenses totaled about $2.83 million, including long-term accrued expenses. The balance sheet reported short-term notes payable, net of discounts, of $907,242; management separately stated that approximately $1.131 million of convertible-note principal was due July 23, 2015 if not converted or redeemed.
Material changes versus the prior comparable period
- Revenue increased by about $81,000. Q1 2015 revenue included five STREAMWAY systems and disposable sales totaling approximately $84,000.
- Gross profit increased, but management attributed the roughly 37% gross margin to free replacement of earlier units with a newer iteration and said margins remained variable.
- Net loss narrowed substantially. The statement of operations reports general and administrative expense of negative $127,795 in Q1 2015 versus $1,179,281 in Q1 2014. Management attributed the year-over-year reduction primarily to waivers of prior-year unpaid bonuses, lower stock and investor-relations compensation, and reduced legal, audit, and financing-related fees.
- Interest expense rose to $153,622 from $18,123, mainly because of interest and debt-discount amortization on convertible notes issued in 2014.
- Operating cash use fell sharply, but management said this reflected, among other things, increased payables and accrued liabilities and lower inventory and prepaid expenses. No financing cash was raised in Q1 2015, compared with $1.87 million of financing cash inflow in Q1 2014.
Outlook, liquidity, risks, and unusual items
- Going concern and funding: The filing says recurring losses and the stockholders’ deficit raise substantial doubt about the company’s ability to continue as a going concern. Management anticipated net losses at least through the next two quarters of 2015 and reported ongoing negative operating cash flow of approximately $250,000 per month. The company was pursuing a proposed public offering and additional private financing, but gave no assurance either would be completed or sufficient.
- Near-term obligations: Management reported approximately $6.37 million of past-due or 2015-due debts, liabilities, and cash obligations at March 31, 2015, and said the amount had continued to increase. The company had delayed payments to vendors and service providers; unpaid balances could lead to supply interruptions, claims, asset remedies, or reduced or suspended operations.
- Post-quarter financing: The company disclosed an April note with $125,000 original principal sold for $100,000 and a May note with $150,000 original principal. Management said April and May private note sales generated $100,000 and $150,000, respectively; proceeds were or would be used for essential operating needs. The notes are substantially similar to the 2014 convertible notes.
- Sales outlook: Management expected revenue to grow as hospitals complete trials and place orders for billable units, and expected margins to improve with more consistent manufacturing and volume purchasing. These are expectations, not quantified guidance. The company had sold 82 STREAMWAY units to date and had renewed a regional independent-distributor contract.
- Convertible debt and dilution: The 2014 notes mature July 23, 2015, bear 12% interest, and have conversion prices tied to a discount to recent trading prices, subject to a stated cap. Conversion, default, and redemption terms may result in material dilution or cash obligations. At March 31, 448,710 options and 501,245 warrants were outstanding; their effect was excluded from diluted loss per share as anti-dilutive.
- Settlement and litigation: A prior settlement required $500,000 in payments to Marshall Ryan. An April 27, 2015 extension added $50,000, imposed 18% interest on the balance retroactively to specified dates, and set a June 2, 2015 payment deadline, subject to funding-triggered acceleration. Separately, four current or former regional sales managers sued the company on April 29, 2015 over alleged unpaid compensation and other claims; the company said certain amounts were owing and intended to defend the action.
- Product costs and operations: Management said operations expense could increase as shipments and sales efforts expand, and that maintaining inventory and preparing for broader sales could increase costs. The filing also cites dependence on additional capital, uncertain hospital adoption, and potential supplier or vendor disruption.
Most important facts for investors to verify
- Confirm the issuer and filing: the provided document identifies Skyline Medical Inc., not Axe Compute Inc.
- Review the company’s actual cash position, monthly cash use, past-due obligations, and ability to meet the July 2015 note maturity and settlement payments.
- Check the status, terms, and proceeds of the proposed public offering and subsequent convertible-note financings, including conversion and dilution effects.
- Assess whether hospital trials are converting into paid system orders and whether the company can improve gross margins as management expects.
- Review the full terms and current balances of the Ryan settlement and the employee lawsuit, including any subsequent developments not covered by this quarter’s filing.
- Reconcile the unusual negative general and administrative expense reported for Q1 2015 with the detailed expense discussion and underlying accounting disclosures.